Aptevo Therapeutics Inc.
APVO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $4 | $3 | $11 |
| - Cash | $21 | $9 | $2 | $9 |
| + Debt | $4 | $4 | $4 | $5 |
| Enterprise Value | – | -$1 | $5 | $7 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$8 | -$6 | -$6 | -$6 |
| % Margin | – | – | – | – |
| Net Income | -$8 | -$6 | -$6 | -$6 |
| % Margin | – | – | – | – |
| EPS Diluted | -2.23 | -8.4 | -87.87 | -86.56 |
| % Growth | 73.5% | 90.4% | -1.5% | – |
| Operating Cash Flow | -$7 | -$7 | -$7 | -$6 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$7 | -$7 | -$7 | -$6 |